Despite early detection and intervention, in our study, one patient died (0.22% of all 464 patients receiving CDK4/6 inhibitors) due to ILD-related complications, emphasizing the potentially life-threatening nature of CDK4/6 inhibitor-associated pneumonitis. Here, CDK4 is linked to interstitial lung disease.